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Abstract
Stroke, one of the most debilitating cerebrovascular and nuerological diseases, is a serious life-threatening
condition and a leading cause of long-term adult disability and brain damage, either directly or by secondary
complications. Most effective treatments for stroke are time dependent such as the only FDA-approved therapy,
reperfusion with tissue-type plasminogen activator; thus, improving tissue oxygenation with normobaric
hyperoxia (NBO) has been considered a logical and potential important therapy. NBO is considered a good
approach because of its potential clinical advantages, and many studies suggest that NBO is neuroprotective,
reducing ischemic brain injury and infarct volume in addition to improving pathologic and neurobehavorial
outcomes. However, increased reactive oxygen species (ROS) generation may occur when tissue oxygen level
is too high or too low. Therefore, a major concern with NBO therapy in acute ischemic stroke is the potential
increase of ROS, which could exacerbate brain injury. The purpose of this review is to critically review the current
literature reports on the effect of NBO treatment on ROS and oxidative stress with respect to acute ischemic stroke.
Considering the available data from relevant animal models, NBO does not increase ROS or oxidative stress if applied
for a short duration; therefore, the potential that NBO is a viable neuroprotective strategy for acute ischemic stroke is
compelling. The benefits of NBO may significantly outweigh the risks of potential increase in ROS generation for the
treatment of acute ischemic stroke.
Introduction
Stroke is one of the most common causes of death and
long-term disability of adults, and as the brain is highly
sensitive to hypoxia insufficient brain oxygen plays a cru-
cial role in the primary and secondary events leading to
neuronal cell death and damage [1–3]. Currently, systemic
thrombolysis with tissue-type plasminogen activator re-
mains the only FDA-approved reperfusion strategy for
acute ischemic stroke [4], which must be given during the
early onset of stroke and delayed therapy significantly
increases the risks of intracranial hemorrhage [5]. For this
reason, improving tissue oxygenation with oxygen therapy
has been considered a logical and potentially important
therapy for acute ischemic stroke. As adequate cerebral
oxygen supply is crucial to neuron survival, the rational
for this approach is to restore cellular oxygenation of dam-
aged neurons, particularly in the penumbra, compromised
after ischemic stroke, and stimulate those damaged neu-
rons to function normally. Specifically, normobaric hyper-
oxia (NBO) may be especially useful for improving brain
tissue oxygen [6–9]. NBO is considered a good approach
because of its potential clinical advantages. It is inexpen-
sive, non-invasive, can be widely available and simple to
administer to acute stroke patients by medical staff in a
broad range of conditions, including by paramedics or at
home. In accord, there are many studies that suggest that
NBO is neuroprotective and can reduce acute ischemic
brain injury, reduce infarct volume and improve patho-
logic and neurobehavorial outcomes [10–26].
Electron paramagnetic resonance (EPR) oximetry studies
highlight the importance of monitoring tissue oxygen dur-
ing acute ischemic stroke and NBO treatment [13, 17, 27].
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EPR studies have shown that NBO treatment applied
during ischemia restores penumbra tissue back to or
above preischemic levels [13, 17, 27], while NBO during
reperfusion increases penumbra tissue oxygen to twice
preischemic levels [17]. As the ischemic penumbra is
considered the main target of oxygen therapy, increased
oxygen status in the penumbra can improve metabolic
status and survival of tissue, but more importantly may
also trigger the generation of reactive oxygen species
(ROS) and oxidative damage when brain tissue oxygen
levels are too high or too low [28, 29]. Thus, a major
concern with NBO in acute ischemic stroke is the po-
tential increase in the generation of ROS, thereby ex-
acerbating brain injury [7]. In this review, we will
discuss the history of oxidative stress with respect to is-
chemia and hyperoxia, and the existing controversy sur-
rounding NBO and oxidative stress, particularly from
relevant experimental models. We will also summarize
the current literature on the impact of NBO treatment
on oxidative stress in acute focal ischemia stroke ani-
mal models, and if potential NBO induced oxidative
stress offset the suggested neuroprotective properties of
NBO.
Oxidative stress in ischemia/reperfusion injury and the
evolution of oxygen treatment
The concept of oxidative damage results from the pro-
duction of ROS and byproducts at rates which exceed
the ability of natural antioxidant defense mechanisms
to detoxify these deleterious products, likely promoting
damage. It has been suggested that ROS and oxidative
stress is an important mechanism in ischemic/reperfusion
injury when ischemia is long and when conditions allow
for oxygen to be restored to the ischemic tissue [30–34].
Reintroduction of oxygen to ischemic tissue may trigger a
series of harmful reactions leading to the production of
ROS and as a consequence inflammation and oxidative
damage rather than the restoration to normal function.
Accordingly, oxygen therapy or hyperoxia may contribute
to oxidative ischemic/reperfusion injury by introducing a
compliment of ROS and oxidative stress.
The idea that hyperoxia causes oxidative stress dates
back to a novel study hypothesizing that the similarities
between the toxic effects of oxygen toxicity and gamma
radiation in mice were associated with the production of
ROS [35]. Many brain specific studies, beginning in the
early 1960s, would then provide supporting evidence of
the involvement of ROS in oxygen toxicity by hyperoxia
either by an increase in ROS, increase in lipid peroxida-
tion, or circumstantial evidence from studies using
agents to effect antioxidant mechanisms and pretreat-
ments to make animals tolerant to hyperoxia [36–53].
However, in a number of these studies, hyperbaric oxy-
gen (HBO) treatment, 100 % oxygen at a pressure
greater than 1 atm absolute, was used as the model for
hyperoxia and oxygen toxicity. HBO will not be discussed
in detail herein, but in clinical trials for ischemia, HBO
has shown mixed outcomes [54–58]. Subsequently, recent
review articles have provided detailed findings on the ef-
fects of HBO on ischemia and oxidative stress in animal
studies [7, 59–61]. While controversial, these reviews have
emphasized that HBO is associated with increased oxida-
tive stress in several studies, mainly linked to excessive
duration of exposure along with high concentrations and
pressures. Likewise, differences in experimental conditions
and trial design in clinical trials have been recognized as a
contributing factor for the mixed results and more con-
trolled studies are needed to determine the effectiveness
of HBO treatment.
The risks of NBO induced oxidative stress are also
suggested to be associated with duration or prolonged
exposure [21, 62, 63]. In addition, the degree of hyperoxia,
composition of the inhaled gas mixture, age (especially
neonatal vs adult), health and species of animal may play a
significant role in determining the therapeutic potential of
NBO [37, 48, 64–67]. Thus far, there are a small number
of clinical trials using NBO as a potential treatment for
ischemic stroke, and mostly all have shown either a poten-
tial benefit or no effect [15, 16, 20, 22, 24] with one trial
cautioning the use of NBO when given for 24 h [68]. To
date, no trials have provided evidence that NBO was detri-
mental. One clinical study in particular has shown NBO
to be neuroprotective when applied within 12 h after the
onset of stroke, and these positive results, despite the
small sample size, call for further studies to investigate the
optimal time window for NBO duration and effects in dif-
ferent types of stroke [15]. Even though neurological out-
comes are promising in clinical trials of NBO, the
uncertainty of potential damage from NBO induced oxida-
tive stress which may aggravate ischemia/reperfusion in-
jury remains a concern. However, many animal studies
have presented findings on the use of NBO treatment
in focal acute ischemia/reperfusion injury models, and
its effects on the formation of ROS, reactive nitrogen
species (RNS) or increased oxidative stress, if any, were
reported. These studies are summarized in the follow-
ing sections (Table 1).
The Effect of NBO on oxidative stress in focal acute
ischemia animal models
Initially, we will review a series of studies in which
NBO is given shortly after the onset of focal acute
ischemia and the impact NBO has on oxidative stress
under these conditions. In 1991, a study by Agardh CD
et al. found that NBO following brief 15 min periods of
ischemia, by bilateral carotid artery occlusion, did not
lead to enhanced H2O2 production and that there was
no indication that postischemic oxygen supply altered
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Table 1 Summary of neurological outcomes in acute focal brain ischemia NBO studies that measure oxidative stress
Model NBO intervention Oxidative stress results Neurological outcome results Ref.
MCAO (2 h) and reperfusion
(60 min ) in rats
NBO (100 % O2) during MCAO
and reperfusion
NBO did not increase HO-1 induction and protein carbonyl
formation (no significant differences between groups)
NBO significantly reduced total infarct volume (70 %) and cortex
infarct volume (92 %), but not significantly in the striatum. No
significant differences in BBB damage.
[12]
MCAO (1,2,3, or 4 h) in rats NBO (100 % O2) during MCAO NBO did not increase markers for O2·
− generation (Het)
(no significant differences between groups)
NBO groups improved neurological scores and had significantly
smaller infarct volumes after 1,2, and 3 h MCAO
[14]
MCAO (90 min) and reperfusion
(90 min) in rats
dNBO (95 % O2) during MCAO
or rNBO during reperfusion
dNBO (not rNBO) significantly reduced 8-OHdG
production. dNBO and rNBO did not affect O2·
−
generation (Het).
NBO during MCAO significantly reduced infarct volume (40 %).
NBO during reperfusion reduced infarction volume (15 %: not
significant)
[17]
MCAO (90 min) and reperfusion
(22.5 h) in WT and gp91phox-KO
mice
NBO (95 % O2) during MCAO NBO significantly inhibited gp91phox expression, NADPH
oxidase activity, and MMP-9 induction in WT
NBO treatment and gp91phox-KO significantly reduced BBB
damage. Inhibition of gp91phox may be an important mechanism
underlying NBO-afforded BBB protection
[23]
MCAO (90 min) and reperfusion
(90 min) in mice
dNBO (100 % O2) during MCAO
or rNBO (100 %) during
reperfusion
dNBO significantly decreased levels of 4HNE, NT, 8-OHdG
oxidation. No significant differences with rNBO
dNBO significantly reduced infarct volume (~50 %) and
improved sensorimotor scores. rNBO worsened the ischemic
lesion, but no significant difference in sensorimotor scores
[27]
BCAO (15 min) and blood
pressure (50 mmHg) reduction in
rats
NBO (100 % O2; 3 h) after
BCAO
NBO did not lead to enhanced H2O2 or ROS production
(no significant differences between groups)
No significant differences in caudoputaminal and neocortical
damaged neurons score or percent of hippocampal necrotic
neurons
[32]
MCAO (90 min) and reperfusion
(22.5 h) in rats
NBO (95 % O2) given during
MCAO
NBO significantly inhibited gp91phox expression and
NADPH oxidase activity
NBO significantly reduced MRI ADC lesion volume (37 %) [67]
MCAO (90 min) and reperfusion
(22.5 h) in rats
iNBO (100 % O2), sNBO, nNBO,
or cNBOa
iNBO and nNBO groups significantly decreased O2·
−
production (Het)
iNBO significantly reduced infarct volume (34 %) equivalent to
nNBO. sNBO did not decrease infarct volume and cNBO did not
improve protection over iNBO or nNBO
[69]
MCAO (90 min) and reperfusion
(22.5 h) in rats
NBO (100 % O2) given for 2,4
or 8 h 30 min after MCAO
NBO (2,4 and 8 h) significantly reduced 8-OHdG and
gp91phox production (greatest reduction with 8 h NBO)
NBO (2,4 and 8 h) significantly reduced total infarct volume and
infarct volume in the cortex and subcortex (8 h NBO offered the
greatest efficacy)
[70]
MCAO (90 min) and reperfusion
(22.5 h) in rats
NBO (95 % O2) given during
MCAO
NBO significantly inhibited gp91phox expression, NADPH
oxidase activity, and MMP-9 induction
NBO significantly decreased BBB permeability coefficient (MRI)
and brain edema
[71]
MCAO (90 min) in WT and
SOD2-KO mice
NBO (100 % O2) (60 min)
started 25 min after MCAO
NBO significantly decreased O2·
− generation (Het) in WT
mice.
NBO does not affect infarct size in SOD2-KO mice and the effect
of NBO on infarct size in WT mice was not presented
[72]
MCAO (10,30,60 or 90 min)
in rats
NBO (95 % O2) given during
MCAO
NBO significantly delayed and attenuated ·NO production
(NOx−:nitrite plus nitrate) and significantly reduced 3-NT
formation
NBO significantly decreased total infarct volume, particularly in
the cortex, but not significantly in the striatum
[73]
MCAO middle cerebral artery occlusion, HO-1 heme oxygenase-1, O2 ·
− superoxide, Het dihydroethidium, dNBO during MCAO, rNBO during reperfusion, 4HNE 4-hydroxynonenal, NT nitrotyrosine, 8-OHdG 8-hydroxy-2′–
deoxyguanosine, BCAO bilateral carotid artery occlusion, WT wild-type, KO knock-out, iNBO Intermittent, sNBO Short, nNBO normal or continuous, cNBO combination, ·NO nitric oxide














the productions of ROS [32]. Singhal AB et al. indicated
that NBO treatment during a filament model of transient
middle cerebral artery occlusion (MCAO) ischemia/
reperfusion did not increase oxidative stress as measured
by heme oxygenase-1 induction and protein carbonyl for-
mation [12]. The same group also indicated that NBO did
not increase markers for superoxide (O2·
−) generation,
measured by dihydroethidium (Het) fluorescence [14]. In
these studies, no significant difference was observed be-
tween NBO and non-treatment animals suggesting that
NBO neither increased nor decreased oxidative stress or
ROS formation.
In a series of studies by the Liu group, it was shown that
NBO treatment, given intermittently or continuously,
during MCAO (90 min) either had no effect or reduced
O2·
− generation as measured by the Het fluorescence
[17, 69]. The generation of 8-hydroxy-2′–deoxyguanosine
(8-OHdG), a biomarker for oxidative DNA damage, was
also reduced compared to non-treatment animals [17, 70].
Alongside, an increase in ROS and 8-OHdG was not ob-
served in the contralateral hemispshere of the ischemic
animals given NBO suggesting that the brain is more tol-
erable to hyperoxia [17]. Follow up studies indicated that
NBO inhibited the upregulation of nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase catalytic sub-
unit, gp91phox, along with the expression of mRNA and
protein of gp91phox. It was concluded that NBO reduced
NADPH activity, a principal enzyme responsible for O2·
−
generation [67, 69, 71], and a subsequent study would
then suggest that gp91phox containing NADPH oxidase
was an important mechanism in NBO-afforded neuropro-
tection in ischemia using gp91phox knock-out mice [23].
Of note, Yaun Z et al. also demonstrated that NBO for
8 h starting during ischemia and continued during re-
perfusion was the most effective at decreasing oxidative
stress compared to shorter durations [70]. Likewise, a
study by the Veltkamp group indicated that O2·
− forma-
tion, again measured by Het, significantly decreased in
mice treated with NBO during ischemia compared to
room air controls, while superoxide dismutase (SOD) 2
knock-out mice, genetically susceptible to ROS-induced
brain injury, were unaffected by NBO suggesting that
NBO does not appear to promote damage associated
with ROS [72].
Similar reports also support the hypothesis that NBO
does not increase ROS production or oxidative stress
when given during reperfusion. In the Liu S et al. study
reviewed above, NBO given during reperfusion (90 min)
instead of ischemia exhibited no difference in ROS and
8-OHdG production compared to control animals [17].
Rink C et al. showed that NBO given during reperfusion
(90 min) did not significantly increase histochemical
markers of oxidative stress, 4-hydroxynonenal (4HNE) (a
measure of lipid peroxidation), the protein nitrotyrosine
(NT) and 8-OHdG oxidation, in the ischemic hemisphere
compared to room air controls [27]. Of note, in the same
study, Rink C et al. showed that NBO given during
MCAO decreased levels of 4HNE, NT and 8-OHdG oxi-
dation in the ischemic hemisphere compared to room air
controls [27] similar to previous studies [17, 70].
The effect of NBO on RNS has also been investigated
in an acute ischemia small animal model. In an earlier
study by Yuan et al., they showed that NBO treatment
during MCAO delayed and attenuated nitric oxide
(·NO) production via the measurement of nitrite plus
nitrate (NOx−), presumably by inhibiting neuronal ni-
tric oxide synthase (nNOS) [73]. Specifically, ischemia
caused a rapid production of ·NO 10 min after stroke
onset and NBO delayed this up to 30 min and de-
creased the total amount of NOx− produced. NBO also
inhibited the oxidative stress marker, 3-NT, similar to
the nNOS inhibitor, 7-nitroxindazole, compared to un-
treated rats [73].
Collectively, all of these studies suggest that short dur-
ation of NBO treatment does not promote additional
oxidative stress in acute ischemic animal models and
may potentially decrease oxidative stress or ROS/RNS
depending on experimental conditions (Table 1). As a
majority of acute ischemia experimental studies mostly
focus on acute 24 or 48 h outcomes, the question can
be raised that more time may be needed for secondary
events to develop with NBO treatment and thus we
may be monitoring different aspects of oxidative stress
mechanisms [38]. For clinical translation, it may be
advantageous to show that NBO does not promote
oxidative stress outside the acute 48 h window or at
least that any effect is extraneous, which current stud-
ies, herein, support and the long term benefits of NBO
treatment suggests [26]. That said, the mechanisms
underlying the effect of NBO on oxidative stress are still
not fully understood and further investigations are
needed.
NBO afforded neuroprotection in focal acute ischemia
animal models
Seeing that a large pool of evidence suggests that NBO
does not increase oxidative stress in acute ischemic stroke
or may possibly decrease oxidative stress dependent on
experimental condition, many of these studies also insinu-
ate that NBO affords neuroprotection or does not worsen
neurological outcomes in acute ischemic stroke. Uninter-
rupted or continuous NBO given shortly after ischemia
decreased infarct volume significantly in many of the stud-
ies [12, 17, 27, 70, 72, 73]. It was even demonstrated in a
novel study by Liu et al. that intermittent NBO and a
combination of intermittent and continuous NBO, given
during MCAO, significantly reduced infarct volume [68].
Similarly, measurements of lesion volume, a compliment
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to infarct volume, by MRI apparent diffusion coefficients
was also significantly reduced in a study wherein NBO
was given during MCAO [67]. This study was in agree-
ment with several clinical studies which demonstrate
improvement of clinical deficits and MRI abnormalities
[15, 16, 20, 24]. Additionally, NBO given during MCAO
was shown to reduce BBB damage and brain edema, a
measure of oxidative damage [70], and more recently,
Sun et al. indicated that NBO therapy had no effect on
infarct volume in SOD2 knockout mice, again suggest-
ing that NBO did not appear to promote damage
inflicted by ROS [72].
The neuroprotective benefits of NBO have also been
investigated when given during reperfusion. In the study
conducted by Liu S et al., in which NBO given during is-
chemia reduced infarct volumes, it was determined that
NBO given during reperfusion had no significant effect
on infarct volume [17]. However, in a similar study, Rink
et al. indicated that while NBO given during ischemia
reduced infarct volume, NBO given during reperfusion
significantly exacerbated the ischemic lesion. [27]. In the
same study NBO given during reperfusion had no sig-
nificant effect on sensorimotor assessment and did not
exhibit elevated levels of oxidative stress suggesting
other factors may be involved. The authors commented
that timing of NBO treatment is crucial in determining
the benefits of NBO, and the mixed outcomes of these
studies warrants further investigation. Nonetheless, in a
study investigating the relationship between outcome
and NBO duration, Yuan Z et al. showed that NBO
given for 8 h, started during MCAO and continued
during reperfusion, offered greater efficacy at reducing
infarct volume compared to NBO given for 2 and 4 h
[71]. In this study, NBO treatment started during ische-
mia and extended into the reperfusion window seem-
ingly improved the benefits of NBO.
In addition to infarct volume, neurological score
assessments have been used to address NBO afforded
neuroprotection or damage in studies investigating
NBO treatment and acute ischemic stroke. In a study
wherein NBO was given during ischemia, Kim et al.
showed that NBO did improve neurological scores [14],
while Agardh CD et al. indicated that NBO given
following brief ischemia (15 min) did not enhance or
decrease damage as measured by neurological damage
scores [32]. Conversely, two studies have demonstrated
that NBO preconditioning, although unbefitting for ische-
mic stroke patients, could prevent ischemic/reperfusion
injury or increase ischemic tolerance [21, 25]. Both studies
indicated that NBO preconditioning decreased infarct vol-
ume, significantly, while Chen et al. [25] showed that
NBO also significantly improved neurological scores com-
pared to controls. It was suggested that overactivation of
antioxidant activities [21] and the hypoxia-inducible factor
signaling pathway [25] may play a role in ischemic toler-
ance or protection. Given that NBO preconditioning was
neuroprotective, it was suggested that preconditioning
may be beneficial for those at risk of stroke or in surgeries
involving selective cerebral perfusion [21, 25, 74, 75], but
the potential neuroprotective effects of NBO precondi-
tioning need to be investigated further.
Worthy of note, a study conducted by Shin HK et al.
indicated that NBO treatment, in a distal MCAO model,
reduced infarct volume and improved neurological func-
tion in normal wild-type mice compared to mice with
endothelial dysfunction [76]. It was suggested that the
neuroprotective effects of NBO are critically dependent
on normal endothelial function possibly linked to RNS
production from endothelial NOS, but production of
RNS was not investigated. Notwithstanding, a majority
of the studies in this section support the hypothesis that
NBO treatment is neuroprotective or does not stimulate
additional damage with respect to acute ischemia/reper-
fusion injury. One study, by Esposito et al., even sup-
ports the neuroprotective effects of NBO long term (up
to 2 weeks) in an animal model [26], but if these effects
last for months or years in human patients warrants
further examination. It is also suggested that NBO may
widen the time window for reperfusion [14] and for
combination treatment with other neuroprotective ther-
apies [9], but clearly many investigators agree that be-
cause of considerable differences in clinical studies, firm
conclusions are difficult to make and more studies are
needed to confirm neuroprotection in humans as those
observed in animal studies, herein. The protective mech-
anisms of NBO remain misunderstood and controversial
[77], but it seems well documented that NBO, if applied
shortly after acute ischemia, may provide neuroprotec-
tion particularly when NBO is shown to reduce or not
influence oxidative stress.
The effect of NBO on oxidative stress in other
experimental models
Although the above studies suggest that NBO may be
neuroprotective in acute ischemic models with no adverse
effects related to oxidative stress, the present controversy
surrounding the association between NBO and oxidative
stress may result from conflicting results in various in
vitro, ex vivo and in vivo experimental models and
diseases states. We will first review the relationship be-
tween NBO and oxidative stress in in vitro and ex vivo
models. Cell culture reoxygenation studies which mimic
hyperoxia conditions similar to NBO show an increase in
intracellular ROS (O2·
−, hydrogen peroxide (H2O2),
hydroxyl radicals, and potent oxidants such as peroxyni-
trite) and increased oxidative stress compared to controls
[78–80]. Ex vivo studies of tissue from the lungs, brain,
liver, and kidney of NBO exposed animals also indicate an
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increase in oxidative stress with each organ responding
differently to NBO and severity of injury being time,
dose and exposure dependent [62–64, 80–82]. Taken
together, these in vitro and ex vivo studies strongly associ-
ate NBO with increased oxidative stress, but care should
be taken when interpreting these results as the duration
of hyperoxia or NBO exposure is significant compared
to suggested treatment conditions for acute ischemia
in vivo [11]. Furthermore, hyperoxia conditions in in vitro
studies exposes the cells to much higher oxygen con-
centration (~100 % directly, or 760 mmHg) than in vivo
conditions where actual tissue oxygen level is only
about 30–40 mmHg [13, 17, 27].
The effect of NBO on oxidative stress in permanent
ischemic models has also added to the controversy sur-
rounding NBO treatment. A study using Mongolian
gerbils indicated that NBO (as short as 60 min) given
15 min after bilateral carotid occlusion resulted in sig-
nificant production of lipid peroxidation measured by
pentane production and that animals given NBO, for
3–6 h, displayed significantly higher mortality com-
pared to control animals [83]. It was suggested that the
brain was the likely site of pentane production, but not
confirmed. In a more recent study, Geng et al. indicated
that NBO (given for 6 h) after permanent MCAO had no
significant effect on infarct volume, neurological deficit or
ROS production measured via H2O2 formation. [84]. In
addition, infarct volume was significantly reduced when
NBO was given 45 min after MCA coagulation, while
NBO (given for 60 or 120 min) had no significant effect
on infarct volume in a permanent MCAO model [85]. The
same study indicated that the benefits of NBO were
dependent on the extent and location of permanent ische-
mia, which may explain the differences in results between
studies [85]. Consequently, more controlled studies are
needed to evaluate the effects of NBO in permanent
ischemia.
Moreover, several studies have investigated the effect
of NBO and oxidative stress in brain diseases such as
traumatic brain injury (TBI) and multiple sclerosis.
Thus far, no studies have shown preliminary evidence
of increased oxidative stress from NBO in TBI models;
alongside, there is supporting evidence of possible ben-
efits in animal models [86, 87]. It is emphasized that
results are somewhat controversial, but clinical TBI
studies have shown no impairment from NBO as well
[86, 87]. Similarly, a recent study indicated that NBO
did not exacerbate oxidative stress injury or neuro-
logical outcomes in a collagenase-induced intracere-
bral hemorrhage model [66]. Given that NBO did not
worsen outcomes related to TBI, the study suggests
that NBO, if proven to be beneficial in ischemic stroke,
could be started before a definitive diagnosis is made
to distinguish between ischemic versus hermorrhagic
stroke [88]. Finally, a novel study on multiple sclerosis
showed that NBO, whether brief (1 h) or continued for
7 days did not reveal evidence of increased O2·
− produc-
tion or oxidative damage when compared to animals
breathing room air, and that NBO therapy may be surpris-
ingly beneficial as a treatment for multiple sclerosis that
had not been noticed previously [89].
The results of the studies presented in this section
highlight the mixed results and controversy surround-
ing NBO, oxidative stress and its effectiveness as treat-
ment in several disease models. Differing experimental
conditions, mainly duration of exposure is attributed to
the observed increases in oxidative stress and varying
results, further supporting the hypothesis that long
duration of NBO would likely produce ROS. However,
these studies are dissimilar to acute ischemia models
which theorized that early timing and short durations of
NBO may minimize deleterious effects as shown in many
acute ischemia animal studies, herein; thus, making NBO
a potential neuroprotective treatment for several brain dis-
eases including acute ischemic stroke.
Conclusions
As a potential treatment for acute ischemic stroke,
NBO has distinct advantages over pharmaceutical drugs
such as the ease of diffusibility across the blood–brain
barrier and the mechanism of action may be via mul-
tiple pathways. It is suggested that high concentrations
of oxygen are well tolerated; however, decades of re-
search have cautioned the possible harmful effects of
oxygen treatment and oxidative damage. The claim is
reasonable considering the oxidant radical damage hy-
pothesis which states that increased oxygen availability
produces increased ROS and oxidative stress. Nonetheless,
considering the available data from relevant animal
models that NBO does not increase ROS or oxidative
stress if applied for a short duration, the potential that
NBO is a viable neuroprotective strategy for acute is-
chemic stroke is compelling. The benefits of NBO may
outweigh the risks of potentially enhanced ROS gener-
ation even if deemed clinically relevant. If we can man-
age the variables controlling oxygen delivery for the
best possible clinical outcome, patients could benefit
from receiving NBO at the earliest possible time. The
risk to benefit ratio of oxygen therapy must be balanced
to determine the safest plan for treatment of acute is-
chemic stroke.
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